Share This Page
Suppliers and packagers for VERSACLOZ
✉ Email this page to a colleague
VERSACLOZ
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Douglas Pharms | VERSACLOZ | clozapine | SUSPENSION;ORAL | 203479 | NDA | TruPharma LLC | 52817-601-38 | 1 BOTTLE in 1 BOX (52817-601-38) / 100 mL in 1 BOTTLE | 2018-06-15 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: VERSACLOZ
Introduction
VERSACLOZ, the brand name for clozapine, is a potent antipsychotic medication primarily used in treatment-resistant schizophrenia. Its unique efficacy makes it a critical component in psychiatric medicine, though its manufacturing entails stringent regulatory compliance owing to serious side effects such as agranulocytosis. The global supply chain of VERSACLOZ is intricate, involving specialized pharmaceutical manufacturers and approved suppliers adhering to rigorous quality standards. This article explores the key suppliers, manufacturing landscape, regulatory considerations, and market dynamics for VERSACLOZ.
Manufacturers of VERSACLOZ
Clozapine’s production infrastructure is concentrated among a few licensed pharmaceutical companies. Notably, Daiichi Sankyo and Eli Lilly have historically played prominent roles depending on regional markets and licensing agreements.
-
Daiichi Sankyo
- As one of the primary manufacturers globally, Daiichi Sankyo holds the original patent rights for clozapine and supplies VERSACLOZ under various markets. The company’s manufacturing facilities in Japan and Europe meet the highest Good Manufacturing Practice (GMP) standards, ensuring product safety and efficacy.
- The manufacturer often collaborates with regional generic producers to meet global demand, especially as patent exclusivity periods change.
-
Eli Lilly and Company
- Eli Lilly was the initial developer of clozapine and held the patent before generic proliferation. While originally involved in the development and marketing, the company has shifted focus in recent years, licensing manufacturing rights to other firms for broader distribution.
-
Generic Manufacturers
- Following patent expiration, multiple generic pharmaceutical companies became authorized to produce clozapine, including Teva Pharmaceuticals, Mylan (Viatris), Sandoz, Hikma Pharmaceuticals, and Fresenius Kabi.
- These companies supply generic versions of VERSACLOZ, adhering to strict regulatory guidelines to ensure bioequivalence and safety.
Key Suppliers and Distribution Channels
The supply of VERSACLOZ involves a complex network extending from active pharmaceutical ingredient (API) producers to finished drug manufacturers and distributors:
-
API Suppliers
- The foundation of VERSACLOZ’s supply is the API for clozapine, supplied by specialized chemical manufacturers. Notable players include Wockhardt and certain Chinese and Indian API manufacturers, which must comply with International Council for Harmonisation (ICH) guidelines.
- API quality is pivotal; only those meeting stringent specifications and regulatory approvals are considered reliable suppliers.
-
Formulation and Final Product Manufacturers
- Companies with GMP-certified facilities assemble the API into finished dosage forms—tablets or suspensions.
- Besides original innovators, numerous generic manufacturers operate globally, especially in India, China, and Europe.
-
Distribution and Supply Chain
- Distribution is tightly regulated, with licensed wholesalers and pharmacy networks in compliance with regional authorities such as the FDA (U.S.), EMA (Europe), and others.
- Many regions mandate Risk Evaluation and Mitigation Strategies (REMS) for VERSACLOZ due to its side-effect profile, affecting how suppliers manage logistics.
Regulatory Oversight and Supplier Qualification
Given the profound safety requirements associated with clozapine, regulatory agencies impose strict qualifications on suppliers:
-
FDA (U.S.)
- Suppliers must hold prior approval through the Food and Drug Administration’s Drug Establishment Inspection (DEI) and New Drug Application (NDA). The REMS program mandates regular monitoring.
-
EMA (Europe)
- Only certified manufacturers with validated GMP compliance are authorized to export VERSACLOZ to the European Union.
-
WHO and International Standards
- For countries with burgeoning access, the World Health Organization’s GMP guidelines serve as a baseline for API and finished product qualification.
Supply Chain Challenges
Several factors influence the stability of VERSACLOZ supplies:
-
Regulatory Complexity
- Due to the risk of agranulocytosis, suppliers must implement rigorous testing, including hematology monitoring, which can limit manufacturing and distribution timelines.
-
API Production Bottlenecks
- The complexity of clozapine synthesis and raw material availability has occasionally led to shortages, especially when geopolitical issues or disruptions in API production occur.
-
Patent and Licensing Dynamics
- Patent expirations lead to increased generic competition but also require rigorous quality assurance from new entrants.
-
Global Health Events
- COVID-19 pandemic disruptions affected supply chains, highlighting the need for diversified supplier networks.
Market Outlook and Critical Suppliers
The future landscape for VERSACLOZ suppliers will likely involve:
- Increased localization of API manufacturing to improve resilience.
- Regulatory harmonization to streamline approvals.
- Greater engagement with biosimilar and generic manufacturers to meet global demand.
Major players—Daiichi Sankyo, Teva, Mylan—are expected to retain significant influence owing to their technical expertise, quality certifications, and established distribution channels.
Key Takeaways
- Limited Manufacturing Base: Only a handful of companies, notably Daiichi Sankyo and certain generic manufacturers, supply VERSACLOZ, emphasizing a concentrated supply chain.
- Strict Regulatory Standards: Suppliers must meet rigorous GMP, API quality, and safety standards owing to the drug’s adverse side effects.
- API Production Crucial: API manufacturing capacity directly impacts drug availability; shortages often stem from API supply disruptions.
- Global Regulatory Compliance: Ensuring supplier compliance with regional regulations (FDA, EMA) is vital for uninterrupted supply.
- Market Dynamics: Patent expirations and rising demand for generic versions broaden supplier options but necessitate stringent quality control.
FAQs
1. Who are the primary global suppliers of VERSACLOZ?
Daiichi Sankyo remains the leading manufacturer, with several generic companies—such as Teva, Mylan, Sandoz, and Hikma—generating significant supply post-patent expiry.
2. How is API quality regulated for VERSACLOZ?
API suppliers must adhere to ICH guidelines and obtain regulatory approval from agencies like the FDA and EMA, ensuring consistent purity, potency, and safety.
3. Are there regional differences in VERSACLOZ suppliers?
Yes. While Japan and Europe are dominated by Daiichi Sankyo, Indian and Chinese companies supply APIs and finished products to emerging markets, often under regulatory oversight of local agencies aligned with international standards.
4. What risks threaten the supply chain of VERSACLOZ?
Manufacturing disruptions, raw material shortages, regulatory delays, and geopolitical issues can lead to supply shortages, especially given the drug’s complex manufacturing process.
5. Will new suppliers emerge for VERSACLOZ?
Potentially, especially as patents expire, enabling more companies to manufacture generic versions under strict regulation and quality assurance programs.
References
- Daiichi Sankyo. Corporate website. Available at: https://www.daiichisankyo.com
- FDA. Requirements for drug approval and manufacturing standards. Available at: https://www.fda.gov
- EMA. European Medicines Agency guidelines for medicinal product manufacturing. Available at: https://www.ema.europa.eu
- WHO. GMP guidelines and API standards. Available at: https://www.who.int
- Market reports. Analysis on generic pharmaceutical manufacturing trends.
In summary, the supply chain for VERSACLOZ is characterized by a limited number of high-quality, regulatory-approved suppliers. Their ability to maintain consistent production hinges on regulatory compliance, raw material availability, and manufacturing excellence. For stakeholders, understanding these dynamics is essential for ensuring reliable access to this vital medication.
More… ↓
